Nick Willcox focuses on Immunology, Myasthenia gravis, Autoantibody, Autoimmune regulator and Autoimmunity. His work on Thymoma and Immunoglobulin G as part of general Immunology research is often related to In patient, thus linking different fields of science. His Myasthenia gravis study combines topics in areas such as Antibody and Acetylcholine receptor.
His biological study spans a wide range of topics, including Chronic mucocutaneous candidiasis and Autoimmune polyendocrine syndrome type 1. The various areas that Nick Willcox examines in his Autoimmune regulator study include Gene expression, IRF8 and Cell biology. His study explores the link between Autoimmunity and topics such as Human leukocyte antigen that cross with problems in Cytokine, Interferon alfa and Alpha interferon.
His scientific interests lie mostly in Immunology, Myasthenia gravis, Autoantibody, Thymoma and Acetylcholine receptor. His is involved in several facets of Immunology study, as is seen by his studies on Autoimmunity, Antibody, Epitope, Human leukocyte antigen and Autoimmune regulator. His work on Immunoglobulin G as part of general Antibody research is frequently linked to In patient, thereby connecting diverse disciplines of science.
His study in Myasthenia gravis is interdisciplinary in nature, drawing from both T cell, Endocrinology and Germinal center. His studies in Autoantibody integrate themes in fields like Chronic mucocutaneous candidiasis, Cytokine and Multiple myeloma. While the research belongs to areas of Thymoma, Nick Willcox spends his time largely on the problem of Interferon, intersecting his research to questions surrounding Autoimmune disease.
Immunology, Autoantibody, Myasthenia gravis, Thymoma and Autoimmune regulator are his primary areas of study. His research on Immunology often connects related topics like Virology. As a member of one scientific family, Nick Willcox mostly works in the field of Autoantibody, focusing on Chronic mucocutaneous candidiasis and, on occasion, Interleukin 22 and Interleukin 17.
In his study, Cell type is strongly linked to Gene, which falls under the umbrella field of Myasthenia gravis. His Autoimmune regulator research is multidisciplinary, incorporating perspectives in Autoimmune polyendocrinopathy and Hypoparathyroidism. He has included themes like Autoimmune polyendocrine syndrome type 1 and Mucocutaneous Candidiasis in his Autoimmune polyendocrinopathy study.
His primary areas of study are Immunology, Autoimmune regulator, Chronic mucocutaneous candidiasis, Thymoma and Autoimmunity. Nick Willcox has researched Chronic mucocutaneous candidiasis in several fields, including Autoimmune polyendocrinopathy and Autoantibody. His work in Autoimmune polyendocrinopathy covers topics such as Autoimmune polyendocrine syndrome type 1 which are related to areas like Autoimmune hepatitis, Hypoparathyroidism and Endocrinology.
His work deals with themes such as Interleukin 22 and Mucocutaneous Candidiasis, which intersect with Autoantibody. His Thymoma research incorporates elements of Myasthenia gravis, FOXP3 and MHC class II. His research in Myasthenia gravis intersects with topics in Lymphopoiesis, Cell, Insulin and Antigen.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells.
Britta C. Urban;David J. P. Ferguson;Arnab Pain;Nick Willcox.
Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines
Kai Kisand;Anette S. Bøe Wolff;Katarina Trebušak Podkrajšek;Liina Tserel.
Journal of Experimental Medicine (2010)
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
Maria Isabel Leite;Saiju Jacob;Stuart Viegas;Judy Cossins.
A role for CD36 in the regulation of dendritic cell function
Britta C. Urban;Nick Willcox;David J. Roberts.
Proceedings of the National Academy of Sciences of the United States of America (2001)
Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1
Anthony Meager;Kumuthini Visvalingam;Pärt Peterson;Kaidi Möll.
PLOS Medicine (2006)
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.
Maria Isabel Leite;Philipp Ströbel;Margaret Jones;Kingsley Micklem.
Annals of Neurology (2005)
Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis.
Gary P. Sims;Hiroyuki Shiono;Nick Willcox;David I. Stott.
Journal of Immunology (2001)
Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis
A. Meager;M. Wadhwa;P. Dilger;C. Bird.
Clinical and Experimental Immunology (2003)
The value of animal models for drug development in multiple sclerosis.
Manuel A. Friese;Xavier Montalban;Nick Willcox;John I. Bell.
An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus
Matthieu Giraud;Richard Taubert;Claire Vandiedonck;Xiayi Ke.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: